Quarterly report · Q3
2784.TEDINET S100SVSS
Period2023-04-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥2.18T | 2023-04-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥2.70T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥2.05T | 2022-04-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥29.9bn | 2023-04-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥20.0bn | 2022-04-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥31.2bn | 2023-04-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥32.8bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥30.9bn | 2023-04-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥22.7bn | 2022-04-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥20.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥25.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.8bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥20.9bn | 2023-04-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥14.9bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥1.50T | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥1.34T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.44T | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.04T | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥851.5bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥464.3bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥488.3bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥481.9bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥200.8bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥160.1bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥107.92 | 2023-04-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥48.22 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.42 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.24 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.64 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 30.9% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.4% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 45
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-12-31 | −¥26.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-12-31 | −¥26.2bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-12-31 | ¥290m |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥1.94T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥1.92T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥14.0bn |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥25.9bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥40.0bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥28.2bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥11.7bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥1.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥27.5bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥27.5bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥484m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2023-04-01 → 2023-12-31 | ¥200.4bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2023-04-01 → 2023-12-31 | ¥200.0bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥395m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2023-04-01 → 2023-12-31 | ¥2.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-12-31 | ¥2.21T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-12-31 | ¥2.18T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-12-31 | ¥26.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-12-31 | ¥29.7bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-12-31 | −¥24.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-12-31 | −¥24.1bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥372m |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥1.82T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥1.81T |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥13.1bn |
| jpcrp040300-q3r_E02962-000Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥16.9bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥36.4bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥25.8bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥10.6bn |
| jpcrp040300-q3r_E02962-000Manufacturing Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥992m |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥27.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥27.1bn |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥0 |
| jpcrp040300-q3r_E02962-000Medical Related Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥43m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue | 2022-04-01 → 2022-12-31 | ¥186.8bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥186.3bn |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥429m |
| jpcrp040300-q3r_E02962-000Self Medication Products Wholesaling Businessreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-12-31 | ¥2.07T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-12-31 | ¥2.05T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-12-31 | ¥24.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-12-31 | ¥19.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 381
| Item | Context | Value | Unit |
|---|---|---|---|
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 24135000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -24135000000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1821752000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 186779000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02962-000ManufacturingBusinessReportableSegmentsMember | 36409000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q3r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 27129000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 2072071000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -24135000000 | JPY |
| Net sales | Prior1YTDDuration | 2047935000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 16929000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 1663000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02962-000ManufacturingBusinessReportableSegmentsMember | 992000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q3r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 43000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 19628000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | 372000000 | JPY |
| Operating income | Prior1YTDDuration | 20000000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1924115000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 199966000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02962-000ManufacturingBusinessReportableSegmentsMember | 28230000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q3r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 27490000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2179803000000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 2179803000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 14030000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 395000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02962-000ManufacturingBusinessReportableSegmentsMember | 11732000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q3r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 26158000000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -26158000000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 1938145000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 200361000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02962-000ManufacturingBusinessReportableSegmentsMember | 39963000000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q3r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 27490000000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 2205961000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -26158000000 | JPY |
| Net sales | CurrentYTDDuration | 2179803000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02962-000EthicalPharmaceuticalsWholesalingBusinessReportableSegmentsMember | 25850000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02962-000SelfMedicationProductsWholesalingBusinessReportableSegmentsMember | 2180000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02962-000ManufacturingBusinessReportableSegmentsMember | 1138000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q3r_E02962-000MedicalRelatedBusinessReportableSegmentsMember | 484000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 29654000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | 290000000 | JPY |
| Operating income | CurrentYTDDuration | 29944000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-02-14 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第21期第３四半期(自 2023年10月１日 至 2023年12月31日) |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |